TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Tilray Q2: High Hopes or Harsh Reality?

Benzinga Logo Benzinga By Erica Kollmann
Tilray Q2: High Hopes or Harsh Reality?

Tilray Brands prepares to report Q2 2026 earnings as the cannabis industry faces potential transformation. President Trump's executive order to reschedule marijuana to Schedule III could eliminate the Section 280E tax burden, potentially unlocking millions in annual cash flow. The company launched Tilray Medical USA in December to capitalize on the policy shift, though Wall Street expects a 20-cent loss per share on $210.95 million in quarterly revenue. Investors will scrutinize guidance on U.S. infrastructure investment and how the company deploys its $265 million cash pile.

Insights
SPOT   neutral

Part of technology platform investments


TLRY   neutral

Mixed outlook with both positive catalysts (potential Schedule III rescheduling and tax relief, new medical subsidiary launch) and ongoing challenges (expected Q2 loss, profitability struggles, competitive pressures). The company stands at a crossroads with significant upside potential but uncertain execution.